Startup Gimlet Labs is solving the AI inference bottleneck in a surprisingly elegant way
Gimlet Labs just raised an $80 million Series A for tech that lets AI run across NVIDIA, AMD, Intel, ARM, …
معلومات السوق الآنية عبر فئات الأصول
Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.
Over the last 30 days, AI sentiment for TECH skewed neutral (223 of 506 scored calls).
| المطلع | المنصب | التاريخ | النوع | القيمة |
|---|---|---|---|---|
| Herr Amy E. | Director | May 08 '26 | Option Exercise | 315874,0 |
| Herr Amy E. | Director | May 08 '26 | Sale | 320386,0 |
| JOSHUA MOLHO | Director | May 08 '26 | Proposed Sale | 320417,0 |
| Hippel James | CFO | May 05 '26 | Option Exercise | 2951200,0 |
| Bohnen Shane | SVP - … | May 05 '26 | Option Exercise | 399840,0 |
| Kelderman Kim | Chief Executive … | May 05 '26 | Option Exercise | 1270539,0 |
| Kelderman Kim | Chief Executive … | Apr 22 '26 | Option Exercise | 0,0 |
| Hippel James | CFO | Apr 22 '26 | Option Exercise | 0,0 |
| Kelderman Kim | Chief Executive … | Apr 14 '26 | Option Exercise | 0,0 |
| Bohnen Shane | SVP - … | Apr 03 '26 | Option Exercise | 0,0 |
المصدر: FinViz — قد تكون البيانات متأخرة
أخبار منتقاة بالذكاء الاصطناعي تؤثر على سعر TECH والمشاعر والاتجاه
Gimlet Labs just raised an $80 million Series A for tech that lets AI run across NVIDIA, AMD, Intel, ARM, …
Welcome back to TechCrunch Mobility, your central hub for news and insights on the future of transportation.
Both stocks provide much more upside than downside at current prices.
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.
The U.S. Justice Department said an Iranian security ministry operates the fake activist persona known as Handala, which claimed responsibility …
تحليل متعدد المزودين بالذكاء الاصطناعي